L-type amino-acid transporter 1 (LAT1) expression is predictive of response to autologous stem cell transplantation for multiple myeloma

L-type amino acid transporter 1 (LAT1) plays a key role in cell growth and survival. Overexpression is a common feature of many malignancies to support increased protein synthesis demand. Among patients with multiple myeloma, high LAT1 expression has been shown to be associated higher risk disease but also a higher response rate following treatment with oral melphalan in clinical and pre-clinical models (Isoda, et al, Cancer Sci, 2014; Hathi, et al, J Nucl Med, 2018). Oral melphalan is infrequently used in today's clinical practice; however, high-dose intravenous melphalan is the standard of care for conditioning prior to autologous stem cell transplantation (ASCT).

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Mark Fiala, Scott Goldsmith, Deep Hathi, Monica Shokeen, Ravi Vij, Mark Schroeder Source Type: research